This statistic depicts the percentage of the U.S. population who had anxiety disorders from 1990 to 2021. According to the data, 6.9 percent of the population suffered from an anxiety disorder as of 2021.

This statistic depicts the percentage of the U.S. population who had anxiety disorders from 1990 to 2021, by gender. According to the data, *** percent of males and *** percent of females had anxiety disorders in 2021.

The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness. The survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions,

Introduction

Social Anxiety Disorder Statistics: Social Anxiety Disorder is one of the leading mental health problems in adults in the USA. Due to unhealthy lifestyles and many similar causes, millions of people are suffering from various mental health issues. However, being specific to social phobia, it is a case of fear of social interactions. There is a major difference between having an introverted personality and social phobia.

Social Phobia or Social Anxiety also causes other mental health issues and affects the overall physical and behavioral patterns of the individual. Understanding SAD by Social Anxiety Disorder Statistics is important to help those individuals suffering from the situation.

Phobia Statistics: Living with the fear of something, just like Ron in Harry Potter was afraid of spiders is what phobia is. There are thousands of phobia types, and millions of people around the world are suffering from the disorder. The most common phobia is fear of animals and closed-in spaces. There is no actual prevention of such disorders, but they are treatable. These Phobia Statistics are written in a way to understand the current situation around the world, with well-researched and recent insights from the United States of America. If you are one of the individuals who have any type of phobia, don’t get scared, it’s okay to talk about it! Editor’s choice 40% of the people suffering from Agoraphobia are suffering from severe issues. In the United States of America, the highest number of people have a fear of animals resulting in 40%. As a result of COVID-19, and following cases of Russia and Ukraine, in the month of July 2022, there were 63% of the people globally, had a fear of relative recession. 15 million Americans are suffering from social phobia, resulting in 7.1% of adults and 5.5% of teenagers. 7% of the worldwide population is suffering from panic disorder, 1.6% of these are male and 3.8% are female. According to Phobia Statistics, there are 31.9% of adolescents aged between 13 to 18 years suffer from anxiety disorders. Women are 2 times more likely to suffer from any specific phobias than men. Specific phobias have affected 9.1% of Americans resulting in 19 million of the population. Patients with anxiety disorder are 3 to 5 times more likely to go for a doctor’s visit, while patients with psychiatric disorders are 6 times more likely to be hospitalized for a similar problem. Around the world, 3.6% of the population is suffering from post-traumatic stress disorder, out of these 1.8% are men and 5.2% are women

Objective: This study aimed to understand Black American women's attitudes toward seeking mental health services and using mobile technology to receive support for managing anxiety.

Methods: A self-administered web-based questionnaire was launched in October 2019 and closed in January 2020. Women who identify as Black/African American were eligible to participate. The survey consisted of approximately 70 questions and covered topics such as attitudes toward seeking professional psychological help, acceptability of using a mobile phone to receive mental health care, and screening for anxiety.

Results: The findings of the study (N=395) showed that younger Black women were more likely to have greater severity of anxiety than their older counterparts. Respondents were most comfortable with the use of a voice call or video call to communicate with a professional to receive support to manage anxiety in comparison to text messaging or mobile app. Younger age, higher income, and greater scores for psychological openness and help-seeking propensity increased the odds of indicating agreement with using mobile technology to communicate with a professional. Black women in the South region of the U.S. had twice the odds of agreeing to the use of mobile apps than women in the Midwest and Northeast regions.

Discussion: Black American women, in general, have favorable views toward the use of mobile technology to receive support to manage anxiety.

Conclusion: Preferences and cultural appropriateness of resources should be assessed on an individual basis to increase the likelihood of adoption of and engagement with digital mental health interventions for management of anxiety.

The global Anxiety Disorders Treatment market is projected to reach USD 31.36 billion by 2033, exhibiting a CAGR of 5.5% during the forecast period (2023-2033). The increasing prevalence of anxiety disorders, the growing adoption of digital therapeutics, and the rising awareness of mental health issues drive the market growth. Additionally, the development of novel therapies, such as gene therapy, and the use of artificial intelligence (AI) and machine learning (ML) in the diagnosis and treatment of anxiety disorders, are expected to fuel market expansion. However, the high cost of certain treatments, the potential for adverse effects, and the stigma associated with mental health issues could restrain market growth. Nevertheless, the growing emphasis on mental health awareness, the increasing availability of reimbursement options, and the integration of mental health services into primary care settings are anticipated to provide significant opportunities for market players in the coming years. Key market segments include application (generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder), type (medication, psychotherapy, other therapies), and region (North America, Europe, Asia Pacific, Middle East & Africa, South America). Prominent companies operating in the market include Limbix, DarioHealth, Holmusk, Omada Health, Express Scripts, Click Therapeutics, Akili Interactive, Pear Therapeutics, Iora Health, and Quartet Health. This comprehensive report provides an in-depth analysis of the global anxiety disorders treatment market, focusing on key concentration areas, trends, and market insights. It discusses the impact of regulations, product substitutes, end-user concentration, and M&A activity.

Anti Anxiety Drugs Market Outlook

The global anti-anxiety drugs market size was valued at approximately USD 14 billion in 2023 and is expected to reach around USD 22 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 5.1%. One of the primary growth factors driving this market is the increasing prevalence of anxiety disorders globally, coupled with rising awareness and diagnosis of mental health conditions.

The growing awareness and acceptance of mental health issues have significantly contributed to the demand for anti-anxiety medications. As societies become more open about discussing mental health, more individuals are seeking medical help for anxiety disorders. Governments and non-profit organizations are also playing a crucial role by advocating mental health awareness, which is pivotal in reducing the stigma around these conditions. This heightened awareness is leading to early diagnosis and treatment, thereby driving the market for anti-anxiety drugs.

Technological advancements and innovations in drug delivery systems are also augmenting the growth of the anti-anxiety drugs market. Innovations such as extended-release formulations and novel drug delivery mechanisms are enhancing the effectiveness and patient compliance of these medications. Pharmaceutical companies are investing heavily in research and development to introduce drugs with fewer side effects, which can provide a better quality of life for patients. These advancements are making treatments more accessible and efficient, thereby expanding the market size.

The increasing burden of work-related stress and urbanization is another key factor contributing to the growth of the anti-anxiety drugs market. As urban areas continue to expand, the fast-paced lifestyle associated with city living often leads to higher levels of stress and anxiety. The pressure to perform in highly competitive environments, alongside financial uncertainties, further exacerbates anxiety conditions. Hence, the demand for anti-anxiety medications is rising among the urban population, contributing significantly to the market growth.

Regionally, North America holds the largest share in the anti-anxiety drugs market due to the high prevalence of anxiety disorders and the well-established healthcare infrastructure. Europe follows closely, driven by increasing healthcare expenditure and growing awareness of mental health. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, attributed to increasing urbanization, economic growth, and rising awareness about mental health. Latin America and the Middle East & Africa, though currently holding smaller market shares, are also anticipated to show gradual growth, primarily due to improving healthcare infrastructure and rising awareness about mental health issues.

Drug Class Analysis

The anti-anxiety drugs market is segmented into several drug classes, including Benzodiazepines, Antidepressants, Beta-Blockers, and Others. Benzodiazepines have historically been one of the most commonly prescribed classes of drugs for anxiety disorders due to their rapid onset of action and efficacy in reducing acute anxiety symptoms. Drugs like diazepam, lorazepam, and alprazolam fall under this category. However, their potential for dependence and side effects have led to a cautious approach in their prescription. Despite these challenges, benzodiazepines continue to hold a significant market share due to their effectiveness in treating severe and acute anxiety episodes.

Antidepressants, particularly SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), are increasingly being used to manage anxiety disorders. These medications are preferred for long-term treatment as they address the underlying neurochemical imbalances associated with anxiety. Drugs like fluoxetine, sertraline, and venlafaxine are commonly prescribed SSRIs and SNRIs. The shift towards antidepressants is driven by their lower potential for abuse and better side-effect profile compared to benzodiazepines. This trend is likely to continue, contributing to the growth of the antidepressant segment in the anti-anxiety drugs market.

Beta-blockers, though traditionally used for cardiovascular conditions, are also prescribed for anxiety, particularly performance anxiety. Drugs such as propranolol help manage the physical symptoms of anxiety, such as tachycardia and tremors. The use of beta-blockers is more situational, often prescribed for short-term or specific anxiety-inducing events rather t

Anxiety Disorders and Depression Treatment Market Outlook

According to our latest research, the global Anxiety Disorders and Depression Treatment market size reached USD 18.9 billion in 2024, reflecting a robust industry driven by rising mental health awareness and increasing diagnosis rates worldwide. The market is poised for steady expansion, with a projected CAGR of 4.8% from 2025 to 2033. By the end of 2033, the market is forecasted to attain a value of USD 28.9 billion. This growth is primarily attributed to the escalating prevalence of anxiety and depressive disorders, coupled with advancements in pharmacological therapies and increased healthcare expenditure globally.

One of the most significant growth factors for the Anxiety Disorders and Depression Treatment market is the rising global burden of mental health disorders. The World Health Organization (WHO) estimates that over 300 million people are affected by depression, while anxiety disorders impact more than 260 million individuals globally. This alarming prevalence has led to heightened public health initiatives, government campaigns, and non-profit programs aimed at early diagnosis and intervention. Moreover, the destigmatization of mental health issues, particularly in developed economies, has encouraged more individuals to seek professional help, thereby increasing the demand for effective pharmacological and therapeutic solutions. Pharmaceutical companies are responding by investing in research and development, driving innovation in drug formulations and expanding the available treatment portfolio.

Another crucial driver is the continuous evolution of treatment modalities, including both medication and non-pharmacological therapies. The introduction of novel antidepressants, anxiolytics, and targeted therapies has significantly improved patient outcomes and reduced side-effect profiles. Furthermore, the integration of digital health platforms, telepsychiatry, and online counseling services has broadened access to mental health care, especially for populations in remote or underserved regions. These technological advancements not only enhance patient engagement but also streamline the distribution of medications through online pharmacies, contributing to market growth. As healthcare providers increasingly adopt a personalized approach, combining medication with cognitive-behavioral therapy (CBT) and other psychotherapeutic interventions, the overall effectiveness of anxiety and depression management continues to improve.

In addition to clinical advancements, favorable reimbursement policies and growing insurance coverage for mental health treatments are catalyzing market expansion. Governments and private insurers in several countries are recognizing the economic and social costs associated with untreated mental health conditions and are, therefore, expanding coverage for both pharmacological and therapeutic interventions. This shift is particularly evident in North America and parts of Europe, where legislative changes have mandated parity between mental and physical health coverage. Such policy support not only alleviates the financial burden on patients but also incentivizes healthcare providers to offer comprehensive mental health services, further fueling market growth.

From a regional perspective, North America continues to dominate the Anxiety Disorders and Depression Treatment market, accounting for the largest revenue share in 2024. This leadership is driven by a high prevalence of mental health disorders, advanced healthcare infrastructure, and substantial investments in research and development. Europe follows closely, supported by strong government initiatives and a robust pharmaceutical sector. Meanwhile, the Asia Pacific region is witnessing the fastest growth, propelled by increasing awareness, improving access to healthcare services, and rising disposable incomes. Latin America and the Middle East & Africa are also showing gradual progress, albeit at a slower pace, due to ongoing efforts to overcome social stigma and expand mental health resources.

A survey from 2022 found that around 52 percent of adults in the United States aged 18 to 29 years felt anxious always or often in the past 12 months. This statistic shows the percentage of adults in the United States who stated they always or often felt anxious, depressed, or lonely in the past 12 months as of 2022, by age.

The North America Anxiety Treatment Device report features an extensive regional analysis, identifying market penetration levels across major geographic areas. It highlights regional growth trends and opportunities, allowing businesses to tailor their market entry strategies and maximize growth in specific regions.

This dataset contains key characteristics about the data described in the Data Descriptor Traumatic life experiences and religiosity in eight countries. Contents:

    1. human readable metadata summary table in CSV format


    2. machine readable metadata file in JSON format

IntroductionPublic discussions in the media (e.g., social media and reality shows) about Black women's mental health have become more common. Notably, celebrities have become more vocal about their own mental health challenges and sought to normalize seeking care. This study aimed to gain a better understanding of Black women's: (1) past and current causes of stress, anxiety, and depression, and coping skills used; (2) their attitudes and perceptions toward mental health and receiving mental health treatment; and (3) times in their life they felt anxious or depressed, and what type of support or resources would have been helpful to have access to.MethodsFocus groups were conducted with 20 women (mean age 36.6 years, SD 17.8 years), with 5 participants per group. Descriptive qualitative content analysis of the focus group transcripts was conducted.ResultsResults consistently showed that intersectional identities of being both Black and a woman resulted in feelings of both hypervisibility and invisibility, representation matters when it comes to mental health providers, an increased openness to therapy across age groups, and a willingness to try digital health tools (e.g., smartphone app) for mental health needs. There is still work to be done to normalize mental health treatment among Black women.DiscussionSubgroups within the community (e.g., young adults) have less stigma around mental health and are acting as catalysts for change. Intentional inclusion of Black women in mental health research and evolving treatment paradigms is important to eliminate inequities in access to culturally relevant mental health care.

Anxiety and Panic Disorders Drugs Market Outlook

The anxiety and panic disorders drugs market is projected to witness significant growth, with the global market size expected to reach approximately USD XX billion by 2032 from USD YY billion in 2023, growing at a robust CAGR of Z% during the forecast period. This growth is driven by several factors, including the increasing prevalence of anxiety and panic disorders worldwide, heightened awareness about mental health issues, and advancements in pharmaceutical drug development. The growing demand for effective treatment options and the rising societal recognition of mental health's importance are potent growth catalysts that are expected to propel the market forward over the next decade.

The rising prevalence of anxiety and panic disorders has been one of the primary drivers of market growth. In recent years, there has been a significant increase in the number of people diagnosed with these mental health conditions. This can be attributed to the growing stress levels stemming from hectic lifestyles, work-related pressures, and socio-economic challenges. Additionally, increased awareness and decreased stigma surrounding mental health have encouraged more individuals to seek medical attention, further expanding the patient pool requiring these medications. Consequently, the demand for anxiety and panic disorder drugs is experiencing steady growth, as healthcare providers strive to offer comprehensive treatment options to meet this rising need.

Technological advancements in the pharmaceutical industry have paved the way for the development of novel drugs with improved efficacy and safety profiles. Innovation in drug delivery systems and the discovery of new therapeutic targets have led to the introduction of advanced medications that effectively manage symptoms with fewer side effects. These innovations have garnered the attention of both healthcare professionals and patients, boosting the adoption of newer drugs over traditional therapies. Pharmaceutical companies are heavily investing in research and development to create more targeted and personalized treatment regimens, which is expected to further spur the market's growth in the coming years.

Furthermore, favorable government initiatives and policies aimed at promoting mental health awareness and treatment access have created a supportive environment for market expansion. Many countries have implemented national mental health programs focused on increasing funding for mental health services, improving healthcare infrastructure, and enhancing training for medical professionals. These efforts are aimed at improving diagnosis and treatment rates, thereby driving up the demand for pharmaceutical interventions. The growing collaboration between governments, non-profit organizations, and private sectors has resulted in increased outreach and education efforts, which are anticipated to further accelerate market growth.

Obsessive-Compulsive Disorder Drugs have become an integral part of the broader mental health pharmaceutical landscape. As awareness of obsessive-compulsive disorder (OCD) grows, so does the demand for effective treatment options. These drugs are designed to alleviate the symptoms of OCD, which can include persistent and intrusive thoughts, as well as repetitive behaviors that individuals feel compelled to perform. The development of these medications has been driven by advancements in understanding the neurological underpinnings of OCD, leading to more targeted therapies. Pharmaceutical companies are investing in research to refine these drugs, aiming to improve their efficacy and reduce side effects, thereby enhancing the quality of life for those affected by OCD. As the stigma surrounding mental health continues to diminish, more individuals are seeking help, contributing to the growth of this segment within the mental health drugs market.

Regionally, North America maintains a dominant position in the anxiety and panic disorders drugs market due to its well-established healthcare infrastructure, high diagnosis rates, and significant investment in mental health research. The region's focus on mental health initiatives, coupled with the presence of key market players, contributes to its substantial market share. Meanwhile, Asia Pacific is projected to experience the highest growth rate due to rising awareness levels, economic development, and increasing healthcare expenditure. Other regions, such as Europe and Latin America, also show promising growth potential, driven by emerging marke

The Anxiety Disorders and Depression Treatment Market Report Segments the Industry Into by Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin–norepinephrine Reuptake Inhibitors (SNRIs) and More), by Indication (Major Depressive Disorder and More), by Therapy (Pharmacotherapy, Psychotherapy and More) and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Digital Therapeutics Generalized Anxiety Disorder Market Outlook

As per our latest research, the Digital Therapeutics for Generalized Anxiety Disorder market size reached USD 1.12 billion in 2024, demonstrating robust momentum driven by the increasing prevalence of anxiety disorders and the growing acceptance of digital health interventions. The market is set to expand at a CAGR of 22.5% from 2025 to 2033, with the forecasted market size expected to reach USD 8.52 billion by 2033. This remarkable growth is fueled by technological advancements, rising mental health awareness, and the integration of digital therapeutics into mainstream healthcare systems, making these solutions more accessible and effective for patients worldwide.

One of the primary growth factors propelling the Digital Therapeutics for Generalized Anxiety Disorder (GAD) market is the escalating incidence of anxiety disorders globally. According to the World Health Organization, anxiety disorders are among the most common mental health conditions, affecting hundreds of millions of individuals. The stigma surrounding mental health is gradually diminishing, leading to increased diagnosis rates and a higher demand for accessible treatment solutions. Digital therapeutics offer a discreet, scalable, and cost-effective alternative to traditional therapy, enabling individuals to receive evidence-based interventions from the comfort of their homes. This convenience is particularly significant in regions with limited access to mental health professionals, further driving adoption rates and market growth.

Another critical driver is the rapid advancement of technology and the proliferation of smartphones and connected devices. The widespread availability of high-speed internet and mobile applications has made digital therapeutics more user-friendly and engaging for patients. Innovative features such as real-time progress tracking, personalized feedback, and interactive modules enhance user engagement and therapeutic outcomes. Furthermore, the integration of artificial intelligence and machine learning into digital therapeutic platforms allows for more tailored and adaptive interventions, improving efficacy and patient satisfaction. These technological developments are not only enhancing the effectiveness of digital therapeutics but also expanding their reach across diverse demographic segments.

Regulatory support and growing investment in digital health are also significant contributors to the market's expansion. Governments and healthcare organizations are increasingly recognizing the value of digital therapeutics in addressing the mental health crisis, leading to favorable reimbursement policies and the inclusion of digital solutions in clinical guidelines. Strategic collaborations between digital therapeutic developers, healthcare providers, and payers are facilitating wider adoption and integration into standard care pathways. Additionally, ongoing clinical research and real-world evidence supporting the efficacy of digital therapeutics for GAD are bolstering trust among clinicians and patients alike, further accelerating market penetration.

From a regional perspective, North America currently dominates the Digital Therapeutics for Generalized Anxiety Disorder market, accounting for the largest share due to its advanced healthcare infrastructure, high digital literacy, and supportive regulatory environment. Europe follows closely, with growing acceptance of digital health interventions and increasing investment in mental health initiatives. The Asia Pacific region is poised for the fastest growth, driven by rising awareness, expanding internet penetration, and a large population base. Latin America and the Middle East & Africa are also witnessing steady growth, albeit from a smaller base, as digital therapeutics become more accessible and affordable in these regions.

Product Type Analysis

The Digital Therapeutics for Generalized Anxiety Disorder market is segmented by product type into software applications, devices, and platforms. Software applications represent the largest segment, driven by the proliferation of mobile health apps designed to deliver cognitive behavioral therapy (CBT), mindfulness exercises, and other evidence-based interventions. These applications are increasingly sophisticated, offering features such as real-time progress tracking, interactive exercises, and personalized feedback. The convenience and accessibility of software applications make them highly attractive to users seeking flexible and private mental health support, contributing sig

Digital Therapeutics for Anxiety Market Outlook

According to our latest research, the global Digital Therapeutics for Anxiety market size is valued at USD 1.8 billion in 2024. The market is expected to grow at a robust CAGR of 23.7% from 2025 to 2033, reaching a projected value of USD 13.3 billion by 2033. This remarkable growth trajectory is fueled by increasing awareness of mental health issues, expanding digital health infrastructure, and the growing adoption of evidence-based digital interventions for anxiety management worldwide.

The primary growth driver for the Digital Therapeutics for Anxiety market is the escalating prevalence of anxiety disorders globally, which affects over 300 million people according to the World Health Organization. The rising incidence of mental health conditions, coupled with the stigma associated with traditional therapy, has propelled demand for accessible and private digital solutions. These platforms empower users to manage anxiety symptoms discreetly and effectively, breaking down barriers such as geographical limitations and resource constraints. Additionally, the COVID-19 pandemic has further accelerated the adoption of digital therapeutics as patients and healthcare providers sought remote, scalable, and clinically validated tools to address mental health needs.

Another significant factor contributing to market expansion is the growing body of clinical evidence supporting the efficacy of digital therapeutics for anxiety. Numerous randomized controlled trials and real-world studies have demonstrated that digital cognitive behavioral therapy (CBT), mindfulness-based interventions, and other digital modalities can lead to meaningful reductions in anxiety symptoms. This scientific validation has encouraged regulatory bodies, payers, and healthcare providers to integrate digital therapeutics into care pathways. Furthermore, the increasing penetration of smartphones and internet connectivity worldwide has made these solutions more accessible, particularly in underserved regions, thereby expanding the addressable patient population.

The market is also benefiting from supportive regulatory frameworks and favorable reimbursement policies in key regions such as North America and Europe. Regulatory agencies like the US FDA and the European Medicines Agency have introduced pathways for the approval and commercialization of digital therapeutics, ensuring that products meet stringent standards for safety and effectiveness. This regulatory clarity, combined with growing payer willingness to reimburse for digital mental health interventions, is incentivizing innovation and investment in the sector. As a result, both established healthcare companies and digital health startups are increasingly focusing on developing and commercializing digital therapeutics tailored to anxiety management.

From a regional perspective, North America currently dominates the Digital Therapeutics for Anxiety market, accounting for the largest revenue share in 2024, followed by Europe and the Asia Pacific. The high adoption rate in North America can be attributed to advanced healthcare infrastructure, strong presence of leading digital therapeutics companies, and proactive government initiatives to address mental health challenges. Europe is also witnessing significant growth, driven by increasing mental health awareness and supportive policy frameworks. Meanwhile, the Asia Pacific region is emerging as a lucrative market, fueled by rapid digitalization, rising healthcare expenditure, and a large population base with unmet mental health needs.

Product Type Analysis

The Product Type segment of the Digital Therapeutics for Anxiety market is primarily categorized into Software Applications, Devices, and Platforms. Software applications currently dominate this segment, accounting for over 60% of the total market share in 2024. The widespread adoption of mobile and web-based applications for anxiety management is attributed to their ease of use, cost-effectiveness, and ability to deliver personalized therapy modules. These applications often include interactive exercises, mood tracking, and real-time feedback, enabling users to monitor their progress and adhere to therapeutic regimens more effectively. The continued evolution of user experience design, gamification, and AI-driven personalization is expected to further enhance the appeal and efficacy of software-based digital therapeutics for

When the COVID-19 pandemic began, U.S. college students reported increased anxiety and depression. This study examines mental health among U.S college students during the subsequent 2020–2021 academic year by surveying students at the end of the fall 2020 and the spring 2021 semesters. Our data provide cross-sectional snapshots and longitudinal changes. Both surveys included the PSS, GAD-7, PHQ-8, questions about students’ academic experiences and sense of belonging in online, in-person, and hybrid classes, and additional questions regarding behaviors, living circumstances, and demographics. The spring 2021 study included a larger, stratified sample of eight demographic groups, and we added scales to examine relationships between mental health and students’ perceptions of their universities’ COVID-19 policies. Our results show higher-than-normal frequencies of mental health struggles throughout the 2020–2021 academic year, and these were substantially higher for female college students, but by spring 2021, the levels did not vary substantially by race/ethnicity, living circumstances, vaccination status, or perceptions of university COVID-19 policies. Mental health struggles inversely correlated with scales of academic and non-academic experiences, but the struggles positively correlated with time on social media. In both semesters, students reported more positive experiences with in-person classes, though all class types were rated higher in the spring semester, indicating improvements in college students’ course experiences as the pandemic continued. Furthermore, our longitudinal data indicate the persistence of mental health struggles across semesters. Overall, these studies show factors that contributed to mental health challenges among college students as the pandemic continued.

The North America Pet Noise Anxiety Treatment report provides a detailed analysis of emerging investment pockets, highlighting current and future market trends. It offers strategic insights into capital flows and market shifts, guiding investors toward growth opportunities in key industry segments and regions.

The Anxiety & Depressive Disorder Treatment market, valued at $21.51 billion in 2025, is projected to experience robust growth, driven by rising prevalence of anxiety and depressive disorders globally, increased awareness and reduced stigma surrounding mental health, and the ongoing development of innovative therapies. The market's compound annual growth rate (CAGR) of 5.32% from 2019 to 2024 suggests continued expansion through 2033. Key growth drivers include the introduction of novel antidepressants with improved efficacy and tolerability profiles, a rising adoption of digital mental health solutions, and increased investment in research and development. Market segmentation reveals significant contributions from antidepressant drugs, followed by therapy and devices. Major depressive disorder and obsessive-compulsive disorder constitute major indication segments. Geographic analysis indicates that North America and Europe currently dominate the market, due to higher healthcare spending and advanced healthcare infrastructure; however, the Asia-Pacific region is anticipated to showcase significant growth potential in the coming years fueled by increasing disposable incomes and rising awareness. While challenges such as high treatment costs and potential side effects of certain medications persist, the overall market outlook remains positive, driven by the growing need for effective treatment options and a shift towards more holistic approaches to mental healthcare. The competitive landscape is characterized by the presence of major pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, Eli Lilly, and Pfizer, alongside emerging biotech companies focusing on innovative treatment modalities. These companies are actively involved in expanding their product portfolios, pursuing strategic partnerships, and investing in clinical trials to gain a competitive edge. The market is expected to witness increased consolidation and strategic alliances as companies strive to expand their market reach and diversify their product offerings. The growing demand for personalized medicine and the development of targeted therapies will further shape the market landscape in the coming years. Furthermore, ongoing research into the underlying causes of anxiety and depressive disorders is likely to lead to breakthroughs that will enhance treatment efficacy and ultimately improve patient outcomes. Recent developments include: In March 2022, HMNC Brain Health reported promising top-line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01) in Treatment-Resistant Depression (TRD)., In February 2022, AbbVie submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the US Food and Drug Administration (FDA) for the adjunctive treatment of the major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.. Key drivers for this market are: Increasing Prevalence of Depression, Emerging Novel Biologics. Potential restraints include: Increasing Prevalence of Depression, Emerging Novel Biologics. Notable trends are: Major Depressive Disorder Segment is Expected to Hold a Significant Market Share Over the Forecast Period.